KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Fulgent Genetics (FLGT) Equity Average (2016 - 2025)

Fulgent Genetics (FLGT) has disclosed Equity Average for 10 consecutive years, with $1.1 billion as the latest value for Q4 2025.

  • Quarterly Equity Average fell 1.62% to $1.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 billion through Dec 2025, down 1.62% year-over-year, with the annual reading at $1.1 billion for FY2025, 1.17% down from the prior year.
  • Equity Average hit $1.1 billion in Q4 2025 for Fulgent Genetics, roughly flat from $1.1 billion in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $1.3 billion in Q2 2022 to a low of $685.5 million in Q1 2021.
  • Historically, Equity Average has averaged $1.1 billion across 5 years, with a median of $1.1 billion in 2024.
  • Biggest five-year swings in Equity Average: surged 922.65% in 2021 and later dropped 10.98% in 2024.
  • Year by year, Equity Average stood at $1.1 billion in 2021, then increased by 15.42% to $1.3 billion in 2022, then decreased by 6.12% to $1.2 billion in 2023, then decreased by 5.47% to $1.1 billion in 2024, then fell by 1.62% to $1.1 billion in 2025.
  • Business Quant data shows Equity Average for FLGT at $1.1 billion in Q4 2025, $1.1 billion in Q3 2025, and $1.1 billion in Q2 2025.